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involvement could drive to develop high blood pressure
without significant changes in GFR in this experimental
model of glomerulopathy.
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ANGIOTENSIN II-INDUCED ALTERATIONS IN
G-PROTEINS IN RENAL PREGLOMERULAR
ARTERIOLES FROM YOUNG GENETICALLY
HYPERTENSIVE RATS
S.J. Vyas, C.M. Blaschak, M.R. Chinoy and E.K. Jackson.
Center for Clinical Pharmacology, University of Pittsburgh
School of Medicine, Pittsburgh, PA
Alterations in signaling pathways that regulate cAMP in
renal preglomerular arterioles (PA) may lead to enhanced
renal responsiveness to angiotensin II (Ang II) in young
SHR. Consequently, we examined the effects of low dose
Ang II on the expressions of Gai, Gas, and Gaq in PA from
SHR and correlated these alterations to changes in renal
vascular resistance (RVR), mean arterial pressure (MAP)
and renal cyclic AMP excretion (UcAMP.V). Young prehy-
pertensive (5–6 week old) SHR and WKY rats were treated
with Ang II (35 ng/kg/min, s.c) or its vehicle using osmotic
minipumps for 7 days. Urine was collected over the last 24
hours. Baseline MAP and renal blood flow were then mea-
sured in anesthetized rats and RVR determined. PA were
isolated by iron oxide method. Expressions of Gai-1,2, Gai-3,
Gas and Gaq in membranes were evaluated by Western
immunoblotting. Baseline MAP were not significantly dif-
ferent between SHR and WKY rats. RBF was significantly
lower and RVR was significantly higher in SHR compared to
WKY rats. Ang II significantly increased MAP and RVR in
SHR but not in WKY rats. Compared to WKY rats, PA from
SHR exhibited higher basal expression of Gai-1,2, Gai-3 and
Gas. Chronic infusion of Ang II downregulated the expres-
sion of Gas, Gai-1,2 and Gai-3 in SHR PA but upregulated
these proteins in WKY. Basal levels of Gaq were similar in
PA from the two strains and were downregulated by Ang II
similarly. Basal UcAMP.V was significantly lower in SHR
compared with WKY rats. Chronic Ang II infusion signifi-
cantly increased UcAMP.V in SHR as well as WKY rats.
These data suggest that elevated levels of Gai proteins may
be directly associated with a blunted adenylyl cyclase-cAMP
cascade in PA in early hypertension. Furthermore, the abil-
ity of Ang II to downregulate the expression of Gas in young
SHR but not in young WKY PA may be important for
enhanced renal sensitivity to Ang II in SHR.
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EFFECT OF COMBINATION THERAPY (ANG II
ANTAGONIST, VALSARTAN AND A CALCIUM
CHANNEL BLOCKER) IN A HYPERTENSIVE MODEL
OF DIABETIC NEPHROPATHY
T.J. Allen, B.J. Davis, M. de Gasparo†, M.E. Cooper*.
University of Melbourne, Heidelberg, Australia †Novartis
Pharmaceuticals, Basel, Switzerland
Recently, it has been suggested that in the context of diabe-
tes and hypertension, more aggressive blood pressure tar-
gets should be considered. To achieve these levels of blood
pressure control, it is likely that combination therapy will
need to be used. The present study has explored the role of
the addition of either a dihydropyridine or a non-dihydro-
pyridine calcium channel blocker (CCB) to Ang II antagonist
based treatment in an experimental model of hypertension
and diabetes. The doses chosen for the combination therapy
groups were lower than those used with monotherapy in
order to achieve similar antihypertensive efficacy. Diabetic
(streptozotocin induced) SHR were randomised to no treat-
ment, valsartan (30 mg/kg/day), the non-dihydropyridine
CCB verapamil (20 mg/kg/day), the dihydropyridine CCB
amlodipine (6 mg/kg/day), a combination of valsartan and
amlodipine (20 mg 1 4 mg/kg/day respectively) or valsar-
tan and verapamil (20 mg 1 15 mg/kg/day respectively).
Serial measurements of systolic blood pressure (BP) and
albumin excretion rate (AER) were performed monthly (data
are shown at week 16 for AER and mean of wk 20–28 for
BP). This model was associated with hypertension (control,
217 6 8, diabetic, 200 6 5 mmHg) which was reduced by
most treatments to a similar degree (valsartan 165 6 3,
amlodipine 164 6 2, verapamil 182 6 4, valsartan 1 amlo-
dipine 151 6 3 and valsartan 1 verapamil 169 6 5 mmHg).
Diabetes was associated with a progressive increase in AER
(control 1.5 vs diabetic 17 mg/24 hr). Valsartan retarded the
increase in AER (11 mg/24 hr). Similar efficacy was ob-
served in the valsartan 1 amlodipine combination (9 mg/24
hr) but not with amlodipine alone (16 mg/24 hr) despite
similar effects on blood pressure. No advantage of vera-
pamil versus amlodipine either as monotherapy or in com-
bination with valsartan was observed. The present study
indicates that the combination of an Ang II antagonist and a
dihydropyridine CCB is an effective regimen at reducing
blood pressure and albuminuria in the context of diabetes
and hypertension.
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EFFECTS OF FOSINOPRIL AMLODIPINE
COMBINATION ON MICROALBUMINURIA IN
HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES
R. Fogari*, L. Corradi, L. Poletti, G.D. Malamani*, P. Lazzari,
P. Preti, A. Mugellini and A. Zoppi*. Department of Internal
Medicine and Therapeutics, University of Pavia, Pavia Italy
Aim of this study was to compare the effects of fosinopril
and amlodipine alone or in combination on urinary albumin
excretion (UAE) in NIDDM hypertensives with microalbu-
minuria. We studied 209 microalbuminuric hypertensive
Mean 6 SD G1 (PVA) G2 (Control) p
SBP (mmHg) 140.3 6 6.2 122.8 6 5.0 ,0.01
Cr. Clearance (ml/min) 1.2 6 0.1 1.23 6 0.13 NS
Proteinuria (mg/day) 18.9 6 12.7 6.4 6 3.8 ,0.01
Urine Red Blood Cells/HPF 8.3 6 3 2.1 6 1.8 ,0.01
Mes-Exp Score 1.58 6 0.84 0.2 6 0.39 ,0.01
RVD Score 1.41 6 0.73 0.12 6 0.22 ,0.01
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